Bruker Corporation. (4/17/26). "Press Release: Bruker Launches MyGenius PRO High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026". Munich.

	Region	München (Munich)
	Country	Germany
	Organisation	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Organisation 2	Hitachi High-Technologies Corporation (TSE: 8036)
	Group	Hitachi (Group)
	Product	MyGenius PRO® PCR MDx system
	Product 2	ESCMID Global 2026 Munich (München)
	Index term	Bruker–Hitachi: thermocylcer, –202604 collab co-developm of My Genius PRO/Labospect GA-5 by EliTech + Hitachi High-Tech
	Person	Abramo, Alessandro (Bruker 202604 Director Marketing + Product Management Microbiology + Infection Dx division)
	Person 2	Kostka, Joe (Bruker 202408 Associate Director Investor Relations)

At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.

At launch, the MyGenius PRO® IVDR menu will include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.

The MyGenius PRO® platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation (Hitachi High-Tech), combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.

During a recent interview, Dr. Pierangelo Clerici, President of AMCLI (Italian Association of Clinical Microbiologists), emphasized the importance of high throughput in microbiology laboratories: “Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations.”

The launch of MyGenius PRO® marks a new chapter in Bruker’s Microbiology & Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius®, BeGenius®, a rapidly growing CE-IVD assay menu, and novel LiquidArray® assays for advanced multiplexing and more affordable syndromic panel testing.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

About Hitachi High-Tech

Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provide high value-added solutions in industrial fields such as mobility, environment and energy, etc.

For further information, visit https://www.hitachi-hightech.com/global/en/

Trade Press & Customer Contact:

Alessandro Abramo
Director Marketing & Product Management
Bruker Microbiology & Infection Diagnostics Division
T: +39-348-360-9058
E: alessandro.abramo@bruker.com

Investor Contact:

Joe Kostka
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Record changed: 2026-06-01